Morton Plant Hospital First in Tampa Bay to Use New Treatment for Restenosis

Morton Plant Hospital recently became the first hospital in the Tampa Bay area to use a drug-coated balloon to treat in-stent restenosis. The hospital was ranked #1 in Florida for Cardiac Surgery in 2023 by Healthgrades, where the area’s first robotic-assisted coronary artery bypass surgery took place in early June.

BayCare Medical Group’s Interventional Cardiologist Lang Lin, MD, and her expert team of medical professionals at Morton Plant Hospital performed the first procedure with the drug-coated balloon earlier this month.

Restenosis occurs when an artery that has previously been stented narrows again because of plaque or scar tissue.

Treating in-stent restenosis remains a significant challenge for both patients and cardiologists, even 20 years after drug-eluting stents (which are coated with medicine to keep arteries open) became the standard of care.” Dr. Lin said.

Until now, in-stent restenosis has most commonly been treated in one of two ways: by placing an additional stent in the stent of the artery that has narrowed again or by performing coronary artery bypass surgery. The challenge with two or more layers of stents is that additional stents become less effective and more difficult to treat. Coronary artery bypass surgery has increased risks with older patients and sometimes limited bypass target vessels.

The new drug-coated balloon, AGENT™ from Boston Scientific, was approved by the U.S. Food and Drug Administration (FDA) for commercial use in March. The balloon catheter, the first drug-coated coronary balloon in the United States, reopens the narrowed stent and releases the high concentration of drugs to prevent scar tissue from forming and blocking the artery wall again.

“We are pleased to have the opportunity to offer this cutting-edge treatment to our patients,” Dr. Lin said. “The new technology will help us to treat certain patients with in-stent restenosis without the need for another stent, invasive surgery or brachytherapy (radiation).”

For more information on heart and vascular services at BayCare: BayCare’s Heart and Vascular Services.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version